A dark horse effort to treat Alzheimer’s disease, already marred by a data manipulation scandal, fell short in a randomized trial reported Tuesday afternoon.
Athira Pharma said that Alzheimer’s patients who received its experimental injection fosgonimeton did not decline at a significantly slower rate than patients who received a placebo injection.
The study, known as LIFT-AD, enrolled 554 people with mild or moderate Alzheimer’s. Fosgonimeton recipients did not significantly outperform placebo on two standard scales used for Alzheimer’s disease, or on a measure that combined the two scales into a single score.
This article is exclusive to STAT+ subscribers
Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.
Already have an account? Log in
